Identification of genetic risk factors for atherosclerosis and drug response markers using clinical trials of the cholesterol-lowering drug pravastatin

被引：0
|
作者：
Ranade, K
Squibb, BM
Iakoubova, OA
Devlin, JJ
Kirchgessner, TG
Tsuchihashi, Z
Ploughman, LM
Zerba, KE
Squibb, BM
Packard, CJ
Shepherd, JJ
Sacks, FM
Sabatine, MS
Braunwald, E
White, TE
Gregg, RE
Dracopoli, NC
Shaw, PM
Squibb, BM
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Celera Diagnost, Alameda, CA USA
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2962
引用
收藏
页码：642 / 642
页数：1
相关论文
共 50 条
  • [1] Risk factors for stroke and the effect of cholesterol-lowering therapy with pravastatin
    West, M
    White, H
    Simes, R
    Kirby, A
    Anderson, N
    Hankey, G
    Tonkin, A
    JOURNAL OF HYPERTENSION, 2000, 18 : S17 - S17
  • [2] Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum
    McLean, Kirsty J.
    Hans, Marcus
    Meijrink, Ben
    van Scheppingen, Wibo B.
    Vollebregt, Aad
    Tee, Kang Lan
    van der Laan, Jan-Metske
    Leys, David
    Munro, Andrew W.
    Berg, Marco A. van der
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (09) : 2847 - 2852
  • [3] Genetic factors in the progression of atherosclerosis and response to cholesterol lowering drugs
    van Geel, PP
    Pinto, YM
    Zwinderman, AH
    Jukema, JW
    van Gilst, WH
    WHAT'S NEW IN CARDIOVASCULAR IMAGING?, 1998, 204 : 95 - 100
  • [4] Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
    Schectman, G
    Hiatt, J
    ANNALS OF INTERNAL MEDICINE, 1996, 125 (12) : 990 - 1000
  • [5] Using Genetics To Explore Whether The Cholesterol-lowering Drug Ezetimibe May Cause An Increased Risk Of Cancer
    Lauridsen, Bo K.
    Stender, Stefan
    Frikke-Schmidt, Ruth
    Nordestgaard, Borge G.
    Tybjaerg-Hansen, Anne
    CIRCULATION, 2015, 132
  • [6] Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer
    Lauridsen, Bo Kobbero
    Stender, Stefan
    Frikke-Schmidt, Ruth
    Nordestgaard, Borge G.
    Tybjaerg-Hansen, Anne
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2017, 46 (06) : 1777 - 1785
  • [7] Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE)
    Ishikawa, T
    Ito, H
    Ouchi, Y
    Ohashi, Y
    Saito, Y
    Nakamura, H
    Orimo, H
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (01): : 48 - 65
  • [8] CHIRAL LC OF A CHOLESTEROL-LOWERING DRUG USING SERUM-ALBUMIN MOBILE PHASES
    NOROSKI, JE
    MAYO, DJ
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (01) : 83 - 87
  • [9] Crystal structure of cytochrome P450sca from Streptomyces carbophilus involved in production of pravastatin, a cholesterol-lowering drug
    Ito, S
    Hata, T
    Watanabe, I
    Matsuoka, T
    Serizawa, N
    FASEB JOURNAL, 1997, 11 (09): : A776 - A776
  • [10] What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? Clinical commentary
    Danis, P
    JOURNAL OF FAMILY PRACTICE, 2001, 50 (11): : 927 - 927
12345